Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keplasen hydrochloride pharmacokinetics in moderate hepatic impairment
ChiCTR2400092316Phase 4Not yet recruiting
- Sponsor
- Shulan (Quzhou) Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of keverprazan in erosive esophagitis (EE) and duodenal ulcer (2 arms), sponsored by Shulan (Quzhou) Hospital. Primary endpoint: Pharmacokinetic parameters. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
keverprazan
03
Conditions
erosive esophagitis (EE)duodenal ulcer
Beyond the preview
Go deeper on ChiCTR2400092316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092316.